Comparative Pharmacology
Head-to-head clinical analysis: ROBAXIN 750 versus SOMA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ROBAXIN 750 versus SOMA.
ROBAXIN-750 vs SOMA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methocarbamol, the active ingredient in Robaxin-750, is a centrally acting muscle relaxant. Its precise mechanism is not fully understood, but it is believed to cause general central nervous system depression, possibly through inhibition of polysynaptic reflexes at the spinal cord level.
Centrally acting muscle relaxant; acts at brainstem reticular formation and spinal cord levels to inhibit polysynaptic reflexes, possibly via GABAergic and monoaminergic pathways.
750 mg orally four times daily (total daily dose 3000 mg).
250 mg to 350 mg orally three times daily and at bedtime.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours (methocarbamol); clinical context: short half-life necessitates frequent dosing (q6h) and may lead to fluctuating plasma levels.
Clinical Note
moderateSomatostatin + Cyclosporine
"The serum concentration of Cyclosporine can be decreased when it is combined with Somatostatin."
Clinical Note
moderateSomatostatin + Methylphenobarbital
"The risk or severity of adverse effects can be increased when Somatostatin is combined with Methylphenobarbital."
Clinical Note
moderateSomatostatin + Hexobarbital
"The risk or severity of adverse effects can be increased when Somatostatin is combined with Hexobarbital."
Clinical Note
moderate1-2 hours; prolonged to 3-4 hours in hepatic impairment; parent drug rapidly cleared via CYP2C19 metabolism to meprobamate (active, t1/2 6-16 hours).
Renal: 90-95% as metabolites (mainly conjugated), <1% unchanged; biliary/fecal: minor; <2% eliminated in feces.
Renal: ~60-70% as metabolites (including meprobamate and glucuronide conjugates); fecal: minimal; biliary: negligible.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
Somatostatin + Thiamylal
"The risk or severity of adverse effects can be increased when Somatostatin is combined with Thiamylal."